Eli Lilly has partnered with Dresden-based Seamless Therapeutics to develop a recombinase-based gene therapy for genetically caused hearing loss. Seamless will engineer precise recombinases, while Lilly...
BioNTech shares are off to a strong start in 2026, gaining over 21 percent in both European and U.S. markets. Analysts remain optimistic, with most recommending...
Spain’s Innovative Medicines Platform outlined its 2026 strategy, centered on leadership in clinical trials, biomedical data use, and the future Biotechnology Law. Announced by its coordinating...
The European Commission’s Safe Hearts Plan promotes proactive, precision cardiovascular care using innovation, digitalization, and responsible AI. Spanish radiology and cardiac imaging societies strongly support it,...
CRISPR/Cas systems are vital bioeconomy tools. Researchers discovered a new CRISPR defense using Cas12a3, which uniquely cuts tRNA tails, halting protein synthesis and pushing cells into...
Nvidia and Eli Lilly are launching a joint AI innovation lab in the San Francisco Bay Area to accelerate drug discovery and manufacturing. Backed by up...
Spain’s 2025–2027 Cutting-Edge Healthcare Program aligns health policy with economic growth, innovation and industrial strength. It prioritizes personalized medicine, innovative drug development and manufacturing, digital health,...
In 2025, JAMA highlighted studies shaping medical practice, notably showing GLP-1 drugs cut hospitalization or death in heart failure patients by over 40%, and that shingles...
Haptena Therapeutics, a biotech focused on KRAS-mutated tumors, launched operations and secured €3 million from Claris Ventures. Founded by Chiara Ambrogio and Roberto Chiarle, the company...
Salmoss Biotech, a Chilean startup, is pioneering regenerative medicine by creating bone implants from salmon-bone waste. Used in 360+ surgeries, the technology is safe, biocompatible, and...